Neumora Therapeutics, Inc.
Data quality: 83%
NMRA
Nasdaq
Manufacturing
Chemicals
$2.08
▼
$0.10
(-4.59%)
Mkt Cap: 378.65 M
Price
$2.08
Mkt Cap
378.65 M
Day Range
$2.05 — $2.16
52-Week Range
$0.61 — $3.65
Volume
634,662
Open $2.16
50D / 200D Avg
$2.71
23.38% below
50D / 200D Avg
$2.07
0.47% above
Quick Summary
Key Takeaways
Debt/Equity of 0.15 — conservative balance sheet
Negative free cash flow of -206.44 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-150.41%
Below sector avg (-51.02%)
ROIC-107.43%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
0.15
Below sector avg (0.33)
Current Ratio6.85
Interest Coverage-119.98
Valuation
PE (TTM)
-1.60
Above sector avg (-1.98)
P/B Ratio2.87
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (44 peers)
Peer Comparison
vs Manufacturing sector median (44 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -1.6 | -2.0 |
| P/B | 2.9 | 5.1 |
| ROE % | -150.4 | -51.0 |
| Net Margin % | — | -150.2 |
| Rev Growth 5Y % | — | 9.3 |
| D/E | 0.2 | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -236.93 M |
| ROE | -150.41% | ROA | -117.97% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -206.44 M |
| ROIC | -107.43% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.15 | Current Ratio | 6.85 |
| Interest Coverage | -119.98 | Asset Turnover | N/A |
| Working Capital | 151.24 M | Tangible Book Value | 132.16 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.60 | Forward P/E | N/A |
| P/B Ratio | 2.87 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -54.52% | ||
| Market Cap | 378.65 M | Enterprise Value | 269.14 M |
| Per Share | |||
| EPS (Diluted TTM) | -1.45 | Revenue / Share | N/A |
| FCF / Share | -1.13 | OCF / Share | -1.13 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 87.13% |
| SBC-Adj. FCF | -238.86 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Net Income | -236.93 M | -243.79 M | -235.93 M |
| EPS (Diluted) | -1.45 | -1.53 | -3.63 |
| Gross Profit | — | — | — |
| Operating Income | -241.16 M | -263.46 M | -252.10 M |
| EBITDA | — | — | — |
| R&D Expenses | 176.07 M | 200.93 M | 142.72 M |
| SG&A Expenses | — | — | — |
| D&A | 208,000.0 | 631,000.0 | 668,000.0 |
| Interest Expense | 2.01 M | — | — |
| Income Tax | 130,000.0 | 178,000.0 | 268,000.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Total Assets | 191.05 M | 316.97 M | 496.20 M |
| Total Liabilities | 87.18 M | 29.91 M | 27.12 M |
| Shareholders' Equity | 103.87 M | 287.06 M | 469.08 M |
| Total Debt | 54.53 M | — | — |
| Cash & Equivalents | 182.53 M | 142.15 M | 374.04 M |
| Current Assets | 190.54 M | 314.06 M | 478.28 M |
| Current Liabilities | 32.45 M | 29.89 M | 25.11 M |
{"event":"ticker_viewed","properties":{"ticker":"NMRA","listing_kind":"stock","pathname":"/stocks/nmra","exchange":"Nasdaq","country":"US"}}